Your browser is no longer supported. Please, upgrade your browser.
Settings
PRGO Perrigo Company Public Limited Company daily Stock Chart
PRGO [NYSE]
Perrigo Company Public Limited Company
IndexS&P 500 P/E206.80 EPS (ttm)0.91 Insider Own0.10% Shs Outstand146.28M Perf Week-2.25%
Market Cap27.53B Forward P/E21.18 EPS next Y8.89 Insider Trans-13.00% Shs Float145.59M Perf Month-2.34%
Income128.00M PEG16.44 EPS next Q1.74 Inst Own79.30% Short Float1.09% Perf Quarter-1.04%
Sales4.60B P/S5.98 EPS this Y-48.30% Inst Trans6.70% Short Ratio1.24 Perf Half Y21.99%
Book/sh72.93 P/B2.58 EPS next Y14.67% ROA1.40% Target Price210.20 Perf Year26.81%
Cash/sh5.46 P/C34.48 EPS next 5Y12.58% ROE2.30% 52W Range134.62 - 215.44 Perf YTD12.82%
Dividend0.50 P/FCF27.63 EPS past 5Y-17.60% ROI3.90% 52W High-12.65% Beta0.36
Dividend %0.27% Quick Ratio1.40 Sales past 5Y15.20% Gross Margin37.20% 52W Low39.79% ATR5.85
Employees13500 Current Ratio1.90 Sales Q/Q33.90% Oper. Margin16.40% RSI (14)49.59 Volatility4.37% 2.78%
OptionableYes Debt/Eq0.50 EPS Q/Q-60.20% Profit Margin4.90% Rel Volume0.87 Prev Close183.76
ShortableYes LT Debt/Eq0.49 EarningsAug 05 BMO Payout28.00% Avg Volume1.28M Price188.19
Recom2.30 SMA20-0.99% SMA500.12% SMA2007.68% Volume1,109,400 Change2.41%
Jun-03-15Reiterated B. Riley & Co. Neutral $195 → $216
Apr-27-15Downgrade B. Riley & Co. Buy → Neutral
Apr-22-15Reiterated B. Riley & Co. Buy $189 → $195
Apr-10-15Downgrade Argus Buy → Hold
Feb-06-15Reiterated RBC Capital Mkts Outperform $177 → $175
Nov-12-14Reiterated Argus Buy $160 → $175
Nov-07-14Reiterated RBC Capital Mkts Outperform $169 → $177
Sep-22-14Reiterated RBC Capital Mkts Outperform $160 → $169
May-15-14Reiterated Argus Buy $175 → $160
May-08-14Reiterated B. Riley & Co. Neutral $170 → $157
May-08-14Downgrade RBC Capital Mkts Top Pick → Outperform $187 → $160
Mar-03-14Reiterated UBS Buy $176 → $190
Mar-03-14Reiterated Stifel Buy $165 → $175
Feb-25-14Reiterated CRT Capital Buy $165 → $175
Feb-07-14Downgrade B. Riley & Co. Buy → Neutral
Jan-16-14Reiterated Argus Buy $160 → $175
Jan-07-14Initiated RBC Capital Mkts Top Pick $187
Dec-12-13Reiterated Stifel Buy $150 → $165
Nov-07-13Reiterated Argus Buy $152 → $160
Nov-04-13Reiterated UBS Buy $140 → $160
Aug-27-15 04:23PM  Expect Perrigo To Grow, With Or Without Hostile Mylan at Investor's Business Daily
Aug-26-15 08:51AM  Perrigo Animal Health, Walmart Provide Ultimate Protection for St. Louis Police Patrol K-9s PR Newswire
Aug-25-15 03:31PM  Perrigo CEO Still Pursuing Deals Amid Takeover Feud With Mylan at Bloomberg
02:00PM  Mylan-Perrigo war of words heats up at bizjournals.com
01:55PM  Mylan Fires Back at Perrigo
01:20PM  Mylan Comments on Misleading Statements Made by Perrigo PR Newswire
11:49AM  Hedge Funds Were Opening Positions in These 5 Healthcare Stocks at Insider Monkey
09:22AM  Put Impax, Akorn and Sagent on Your Watch List of Generics Targets at TheStreet
Aug-24-15 07:15PM  Kyle Bass Focuses on Fuel, Pharmaceutical Stocks in Second Quarter
10:10AM  Billionaire James Dinans Top New Stock Picks For Q3 at Insider Monkey
Aug-22-15 01:58AM  Next Week at Barrons.com
Aug-21-15 04:50PM  Mylan prepared to run Perrigo as subsidiary at bizjournals.com
03:19PM  Mylan Clarifies Certain Inaccuracies by Third Parties Related to Lowered Acceptance Condition to Acquire Perrigo PR Newswire
06:20AM  EU Commission clears Perrigo to buy GSK units Reuters
Aug-20-15 08:20AM  Big Catalysts Coming Within a Week for 2 Specialty Pharmaceutical Stocks at 24/7 Wall St.
Aug-19-15 01:04PM  PERRIGO CO PLC Financials
Aug-17-15 12:36PM  Soros, hedge funds loved Time Warner Cable in second quarter at MarketWatch
09:25AM  Moody's: Mylan move pressuring investment grade rating at bizjournals.com
Aug-16-15 11:15AM  5 Trade Ideas for Monday: Anadarko, Expedia, Huntington Bank, Perrigo & Old Dominion
Aug-14-15 09:08PM  Mylan, Perrigo Notch Wins in Their Takeover Fight at The Wall Street Journal
06:31PM  Mylan, Perrigo Notch Wins in Their Takeover Fight at The Wall Street Journal
02:58PM  Dealpolitik: ISS Balks After Mylan's Gutsy Move on Perrigo Bid at The Wall Street Journal
02:30PM  Proxy firm urges Mylan investors vote 'no'; Paulson backs deal Reuters
01:30PM  Paulson & Co. Votes in Support of Mylan's Proposed Merger with Perrigo PR Newswire
01:07PM  Kyle Bass' pharma plays
12:40PM  Paulson & Co. Said to Buy Perrigo Shares: DJ
11:07AM  ISS Affirms Perrigo's Position That Proposed Mylan Transaction Would Be Value Destructive PR Newswire
09:18AM  Mylan Responds to ISS Recommendation Regarding Perrigo Transaction PR Newswire
08:57AM  Proxy firm ISS advises Mylan investors to vote no on Perrigo buy
08:05AM  Proxy adviser ISS recommends Mylan shareholders vote against Perrigo deal at MarketWatch
Aug-13-15 06:36PM  PERRIGO CO PLC Files SEC form 10-K, Annual Report
03:53PM  Some Positives Among The Carnage
02:19PM  Mylan pursues minimum of Perrigo shareholder support for takeover Reuters
01:41PM  Perrigo Comments On Mylan's Reckless Lowering Of Tender Threshold PR Newswire
09:38AM  Faber Report: Mylan persists with battle for Perrigo
09:26AM  Mylan lowers shareholder acceptance bar on Perrigo offer
07:40AM  Mylan pursues Perrigo with lower shareholder support for takeover
07:00AM  Mylan Lowers Acceptance Condition on Perrigo Offer to Greater than 50% PR Newswire
Aug-12-15 05:17PM  PERRIGO CO PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:21PM  Perrigo Company plc Announces Quarterly Dividend PR Newswire
02:09PM  Egan-Jones Joins Glass Lewis in Recommending Mylan Shareholders Vote For Perrigo Transaction Proposal PR Newswire
10:40AM  Proxy firm Glass Lewis recommends Mylan shareholders vote in favor of Perrigo deal at bizjournals.com
10:40AM  Always a good time for M&A until it's not: Pro
09:04AM  Glass Lewis Recommends Mylan Shareholders Vote For Perrigo Transaction Proposal PR Newswire
Aug-11-15 08:43AM  Perrigo Animal Health, Walmart Provide Ultimate Protection for Tampa Police Patrol K-9s PR Newswire
Aug-07-15 02:34PM  Key Analyst Sees Mylan as a Value Play
12:25PM  With Teva Bid Off the Table, Mylan's Stock In 'Show-Me' Mode at The Wall Street Journal
Aug-06-15 11:51PM  Mylans Perrigo Backup Plan at The Wall Street Journal
04:44PM  Mylan claims US 'too shareholder centric' at Financial Times
03:33PM  Mylan CEO says still wants Perrigo but has other options
03:03PM  Mylan's Perrigo Backup Plan at The Wall Street Journal
02:10PM  Bresch: Mylan continues hunt for acquisitions at bizjournals.com
01:46PM  Mylan claims US 'too shareholder centric'
12:43PM  Mylan CEO says does not 'have to' buy Perrigo, has other options
11:09AM  Mylan CEO Says Doesnt Have to Own Perrigo, Eyeing Other Targets at Bloomberg
10:59AM  Mylan CEO says has other options, doesn't 'have to' buy Perrigo
08:14AM  North America generic sales help Mylan's profit beat
12:12AM  Overheard: Perrigos Adjustable Mylan Defense at The Wall Street Journal
Aug-05-15 09:55PM  Overheard: Perrigo's Adjustable Mylan Defense at The Wall Street Journal
07:51PM  Edited Transcript of PRGO earnings conference call or presentation 5-Aug-15 2:00pm GMT
03:30PM  Shire Announces Baxalta Buyout Proposal for $30 Billion - Analyst Blog
02:27PM  Perrigo's Adjustable Mylan Defense at The Wall Street Journal
01:35PM  Perrigo Revenue Rises at The Wall Street Journal
01:21PM  Perrigo CEO says no easy path for Mylan to acquire company
10:52AM  Perrigo Beats on Q2 Earnings, Revenues In Line, Keeps View - Analyst Blog
10:44AM  Mylan Provides Update on Conditions to Perrigo Offer PR Newswire
09:48AM  Perrigo tops Street 4Q forecasts
09:14AM  Perrigo (PRGO) Beats on Q2 Earnings, Outlook Reiterated - Tale of the Tape
08:03AM  Perrigo beats Street 4Q forecasts
07:46AM  Perrigo Company plc Reports Record Quarterly Net Sales, Adjusted Gross Margin, Adjusted Net Income And Cash Flow From Operations PR Newswire
07:07AM  Q4 2015 Perrigo Company PLC Earnings Release - Before Market Open
Aug-04-15 12:25PM  Will Mylan (MYL) Beat Q2 Earnings on New Product Sales? - Analyst Blog
Aug-03-15 04:05PM  Will Perrigo (PRGO) Earnings Disappoint Estimates in Q2? - Analyst Blog
Jul-31-15 02:20PM  Will BioMarin Top Q2 Earnings Again on Vimizim Sales? - Analyst Blog
11:10AM  Mylan Inc. -- Moody's Affirms Mylan's Baa3; outlook changed to negative from developing at Moody's
Jul-29-15 02:53PM  Analysts ask if Mylan can make case with its shareholders for Perrigo purchase at bizjournals.com
10:06AM  Mylan gets European clearance in proposed Perrigo takeover
07:00AM  Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo PR Newswire
06:16AM  EU clears acquisition of Perrigo by Mylan Reuters
Jul-28-15 10:01PM  More tie-ups in generic drug cos expected AAP
03:00PM  What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
01:10PM  There's 'Life After Teva' For Mylan, Says Leerink at Barrons.com
09:44AM  Faber Report: Mylan continues fight for Perrigo
Jul-27-15 06:12PM  Mylan independence from Teva's embrace comes with a price
05:22PM  Teva Tags Allergan's Generics: $40.5 Bil
04:45PM  Mylan to gather shareholders Aug. 28 in Amsterdam to decide Perrigo bid at bizjournals.com
04:43PM  Analysts expect more tie-ups in generic drug business
03:58PM  Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders PR Newswire
03:48PM  Mylan must raise its bid for Perrigo
03:18PM  With Teva out of the way, Mylan clear to focus on Perrigo deal at bizjournals.com
03:14PM  Allergan to own 10% stake in Teva
12:54PM  The $100 Billion Deal Is Still Out There for Pharma: Real M&A at Bloomberg
12:42PM  Trending Now: PRGO
12:11PM  Why Mylan N.V. Stock Slumped Today at Motley Fool
12:08PM  Teva Buys Allergan Unit: How Mylan, Other Biotech Stocks Are Reacting
11:30AM  Teva deal pushes Allergan up, Mylan down; GrubHub downgraded
10:51AM  Teva Drops Mylan Chase To Buy Allergan Generics Unit at Investor's Business Daily
09:09AM  Mylan Shares Plummet as Teva Abandons Takeover for Allergan Deal at Bloomberg
09:09AM  Mylan Shares Plummet After Teva Abandons Takeover for Allergan Deal
07:48AM  Early movers: AGN, MYL, MHFI, UBS, FCAU & more at CNBC
Perrigo Company plc, through its subsidiaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The company operates through Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx Pharmaceuticals), Specialty Sciences, and Other segments. The CHC segment offers OTC products, including analgesics, cough/cold/allergy/sinus, gastrointestinal, infant nutritional, smoking cessation, animal health, feminine hygiene, diabetes and dermatological care, diagnostic, and other healthcare products, as well as vitamins, minerals, and dietary supplements; and contract manufacturing services. It serves retail drug, supermarket, mass merchandise chains, and wholesalers through sales force and industry brokers. The BCH segment provides branded OTC products in the natural health; vitamins, minerals, and supplements; cough, cold, and allergy; personal care and derma-therapeutics; lifestyle; and anti-parasite areas. This segment serves pharmacies, drug, and grocery stores through pharmacy sales force, as well as a network of pharmacists. The Rx Pharmaceuticals segment offers generic and specialty pharmaceutical prescription drugs in various dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, women's health products, oral solid dosage forms, and oral liquid formulations; and ORx products. It serves wholesalers; retail drug, supermarket, and mass merchandise chains; hospitals; and pharmacies. The Specialty Sciences segment provides Tysabri to treat multiple sclerosis. The Other segment offers active pharmaceutical ingredients that are used by generic and branded pharmaceutical companies. The company was founded in 1887 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 25Sale181.371,737315,0400Aug 27 03:32 PM
KINGMA TODD WExecutive VP, General CounselAug 25Sale181.371,715311,05010,320Aug 27 03:32 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 24Option Exercise114.604,468512,0314,131Aug 25 06:21 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 24Sale177.684,468793,8701,737Aug 25 06:21 PM
Jamison Scott FExecutive Vice President PBMAug 21Option Exercise186.89552103,1635,379Aug 25 06:21 PM
Stewart Michael RobertSr. VP Global Human ResourcesAug 21Option Exercise186.89552103,1631,398Aug 25 06:21 PM
Shah JatinSr VP & Chief Scientific OfficAug 21Option Exercise186.89552103,1634,619Aug 25 06:22 PM
Needham JeffreyEVP, GM Consumer HealthcareAug 21Option Exercise186.89967180,7237,646Aug 25 06:20 PM
Kochan SharonEVP, GM InternationalAug 21Option Exercise186.89967180,7237,731Aug 25 06:20 PM
PAPA JOSEPH CPresident and CEOAug 21Option Exercise186.897,3651,376,445123,234Aug 25 06:21 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 21Option Exercise186.891,022191,0022,223Aug 25 06:21 PM
Farrington ThomasSenior VP and CIOAug 21Option Exercise186.89552103,1631,719Aug 25 06:19 PM
Boothe DouglasEVP & GM Perrigo PharmaAug 21Option Exercise186.8939573,822951Aug 25 06:19 PM
KINGMA TODD WExecutive VP, General CounselAug 21Option Exercise186.891,409263,32812,686Aug 25 06:19 PM
Yu LouisExecutive VP Global QualityAug 21Option Exercise186.89552103,1636,327Aug 25 06:20 PM
Brown Judy LExecutive VP & CFOAug 21Option Exercise186.892,578481,80213,621Aug 25 06:20 PM
KINGMA TODD WExecutive VP, General CounselApr 29Option Exercise58.821,70099,99411,064May 01 04:19 PM
KINGMA TODD WExecutive VP, General CounselApr 29Sale190.271,700323,4599,364May 01 04:19 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyApr 14Option Exercise107.058,800941,9974,148Apr 16 04:14 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyApr 14Sale200.278,8001,762,3760Apr 16 04:14 PM
KINGMA TODD WExecutive VP, General CounselApr 13Option Exercise35.851,30046,60510,664Apr 15 02:57 PM
KINGMA TODD WExecutive VP, General CounselApr 13Sale198.441,300257,9729,364Apr 15 02:57 PM
Shah JatinSr VP & Chief Scientific OfficMar 13Sale165.502,000331,0003,291Mar 17 10:50 AM
Yu LouisExecutive VP Global QualityMar 12Sale166.2714023,2784,746Mar 16 04:35 PM
Farrington ThomasSenior VP and CIOFeb 20Sale151.1851778,161321Feb 24 04:26 PM
Farrington ThomasSenior VP and CIOFeb 06Option Exercise0.0079801,119Feb 09 04:37 PM
MORRIS HERMAN JRDirectorNov 14Sale154.4220030,8831,400Nov 17 05:22 PM
Kochan SharonEVP, GM InternationalNov 10Option Exercise90.655,367486,51910,767Nov 12 04:37 PM
Yu LouisExecutive VP Global QualityNov 10Sale155.1125940,1734,886Nov 12 04:33 PM
Kochan SharonEVP, GM InternationalNov 10Sale156.365,367839,1845,400Nov 12 04:37 PM
Brown Judy LExecutive VP & CFONov 03Option Exercise48.923,515171,9539,445Nov 05 04:39 PM
Brown Judy LExecutive VP & CFONov 03Sale160.603,515564,5077,445Nov 05 04:39 PM
Brown Judy LExecutive VP & CFOOct 01Option Exercise48.923,515171,9539,445Oct 02 04:26 PM
Brown Judy LExecutive VP & CFOOct 01Sale150.723,515529,7817,445Oct 02 04:26 PM
Kochan SharonEVP, GM InternationalSep 03Sale150.001,116167,4005,400Sep 04 04:42 PM
KINGMA TODD WExecutive VP, General CounselSep 03Sale150.101,000150,0952,000Sep 03 05:00 PM
Farrington ThomasSenior VP and CIOSep 02Sale150.361,741261,773321Sep 03 05:12 PM
KINGMA TODD WExecutive VP, General CounselAug 29Option Exercise35.851,25044,81310,614Sep 03 05:00 PM
KINGMA TODD WExecutive VP, General CounselAug 29Sale149.301,250186,6259,364Sep 03 05:00 PM